Well now TSRX announced a share offer for $4.75 taking place next week, so we get one last chance to add to TSRX positions before things start to happen. The data for the second phase III should be out in about 2 months. Biotech companies sometimes need to raise cash to continue research and remain in control of their destinies. This should be the last dilution for some time. They are raising $29 million. :#3
Did you see the new Seaking Alpha article out today on TSRX? That article is one of the most comprehensive I have seen on TSRX (packed with Facts about gram-positive infections - MRSA, VRSA), covers the competitive landscape and market potential for TSRX.
I don't mean to high-jack your post to khumb. But I had TSRX in my watch list for few month and now will definitely look for an opportunity to open position at $4.40-4.60 range. I have to re-balance
some of my holdings, including HZNP , which looks promising but is a 50/50 coin flip at this moment, depending on it's sales results. And I rather make my bets in bio stocks based on their development milestones.
I am glad SNTS stock performed so well last year.